Takeda Pharmaceutical Co Ltd (TAK)



Takeda Pharmaceutical Company Limited, a research-based pharmaceutical company, through its subsidiaries, develops, manufactures, and markets pharmaceutical products worldwide. It operates in two segments, Pharmaceuticals and Other. The Pharmaceuticals segment engages in the manufacture and sale of ethical pharmaceutical products in the therapeutic areas of allergy, cardiovascular, central nervous system, diabetes, gastrointestinal, gout, infection, inflammation, interleukin, osteoporosis, and urology and gynecology, as well as vitamins and vaccines. It offers ethical products, including Actos and Actoplus Met, which are used to treat diabetes; Blopress that treats hypertension; Takepron for the treatment of peptic ulcer; Leuplin for the treatment of prostate cancer, breast cancer, and endometriosis; Amitiza that is used to treat chronic idiopathic constipation; and Rozerem that is used to treat insomnia. This segment also provides over-the-counter drugs, including cold remedies, vitamin-containing tonics, athlete's foot treatments, and laxatives. The Other segment engages in the production, marketing, and sale of vitamin bulks, test reagents, clinical diagnostics, inorganic industrial chemicals, photographic chemicals, beverages, and health foods. Takeda Pharmaceutical Company Limited has a strategic partnership with H. Lundbeck A/S for the development and commercialization of Lundbeck's portfolio of novel compounds, Lu AA21004, for the treatment of mood and anxiety disorders. It has a collaboration agreement with AMAG Pharmaceuticals, Inc. The company was founded in 1781 and is headquartered in Osaka, Japan.

Data based on most recent fiscal year report
Market Cap37.95 Billion Shares Outstanding1.562 Billion Avg Volume90.243 Thousand
1-Yr BETA vs S&P TR Current Ratio0.92 Quick Ratio0.76
View SEC Filings from TAK instead.
Q2 2019 All Institutions Hedge Funds 1
To trade TAK now:
Filers who had this stock in their top 10: 7 3 (0.31%)
13F Filers holding this stock: 332 41 (4.24%)
Aggregate 13F shares on 06/30/2019: 144.88 Million 73.028 Million
Aggregate 13F shares on 03/31/2019: 178.913 Million 85.11 Million
Percent change: -19.02% -14.20%
Funds creating new positions: 50 9
Funds Adding to an existing position: 85 9
Funds closing out their position: 85 13
Funds reducing their position: 117 12
Heat Map Ranking for 06/30/2019 97
1 hedge funds as identified by whalewisdom.com through public filings.

Funds Holding TAK (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)


Open Market Sells (S)


Exercise Derivative Conversion (M)


Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments